Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists.

Donovan JL, Schroeder WS, Tran MT, Foster K, Forrest A, Lee TB, Gandhi PJ.

J Manag Care Pharm. 2007 Sep;13(7):598-606.

2.

Antiplatelet intervention in acute coronary syndrome.

Arora RR, Rai F.

Am J Ther. 2009 Sep-Oct;16(5):e29-40. doi: 10.1097/MJT.0b013e31804c7238. Review.

PMID:
19092648
6.

An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.

Adgey AA.

Am Heart J. 1998 Apr;135(4):S43-55. Review.

PMID:
9539495
7.

[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].

Galli M, Maggioni AP, Vassanelli C, Tavazzi L.

Ital Heart J Suppl. 2000 Feb;1(2):202-11. Review. Italian.

PMID:
10731377
8.

Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.

Proimos G.

J Thromb Thrombolysis. 2001 Apr;11(2):99-110. Review.

PMID:
11406724
9.

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.

Lincoff AM, Califf RM, Topol EJ.

J Am Coll Cardiol. 2000 Apr;35(5):1103-15. Review.

10.

Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.

Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM; American Heart Association Council on Clinical Cardiology; Society of Geriatric Cardiology.

Circulation. 2007 May 15;115(19):2549-69. Review.

12.

Clinical pharmacology of eptifibatide.

Phillips DR, Scarborough RM.

Am J Cardiol. 1997 Aug 18;80(4A):11B-20B. Review.

PMID:
9291241
13.
15.

The role of eptifibatide in patients undergoing percutaneous coronary intervention.

Zeymer U.

Expert Opin Pharmacother. 2007 Jun;8(8):1147-54. Review.

PMID:
17516878
16.

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Théroux P, Stone GW, Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA.

Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):448-58. doi: 10.1161/CIRCOUTCOMES.110.960294. Epub 2011 Jun 28. Review.

17.

Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.

Dyke CM.

Am Heart J. 1999 Oct;138(4 Pt 2):307-16. Review.

PMID:
10502236
18.
20.

Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.

Marsh JD.

Am J Health Syst Pharm. 2002 Nov 1;59(21 Suppl 7):S15-26. Review.

PMID:
12434711
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk